1. Home
  2. NCMI vs ARMP Comparison

NCMI vs ARMP Comparison

Compare NCMI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$2.46

Market Cap

244.6M

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$5.59

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCMI
ARMP
Founded
2005
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.6M
199.7M
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
NCMI
ARMP
Price
$2.46
$5.59
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$5.63
$15.00
AVG Volume (30 Days)
1.6M
94.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.20
N/A
Revenue Next Year
$6.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$2.83
52 Week High
$5.03
$14.98

Technical Indicators

Market Signals
Indicator
NCMI
ARMP
Relative Strength Index (RSI) 34.71 57.69
Support Level $2.16 $5.66
Resistance Level $3.74 $6.60
Average True Range (ATR) 0.12 0.48
MACD 0.02 0.09
Stochastic Oscillator 18.39 91.98

Price Performance

Historical Comparison
NCMI
ARMP

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: